7 Stocks to buy for over 20% upside potential – stocks hours what is ledderhose disease

If you’re looking for a quick boost to your portfolio, look no further. Here are 7 stellar stock to buy — and I’ll explain why. First, each of these stocks has over 20% upside potential. This is from the current share price to the average what is ledderhose disease analyst price target. (And some of these stocks have far more than 20% upside potential.) Secondly, all these are ‘Strong Buy’ stocks according to Street consensus — or all the stock’s ratings for the last three months. And last but not least, when you see the analyst investor reports on these stocks, it’s clear that these are very promising companies with serious what is ledderhose disease growth to come.

I found these stocks to buy using TipRanks’ stock screener. This nifty screener enables you to find stocks to buy what is ledderhose disease with a bullish rating from the Street’s best analysts. Plus you can screen for only stocks with 20% upside potential and above. True, the market may look choppy thanks to trade tensions but what is ledderhose disease there are still gems out there. As Thorne Perkin, president of Papamarkou Wellner Asset Management told CNBC: “When you put it all together, this is a healthy time to come into the market what is ledderhose disease for the long term… We always look at these pullbacks as buying opportunities for what is ledderhose disease the long term.”

“Management is balancing short-term profits driven by the impressive increase in television rights what is ledderhose disease with long-term growth by investing back in the franchise, particularly internationally” says Gould. He believes the current softness in key metrics is temporary what is ledderhose disease due to talent injuries. And looking forward the company is on track for double what is ledderhose disease digit top-line growth and 30% compounded EPS growth. Gould also ramps up his price target from $85 to $100. Want to learn more about World Wrestling stock? Get a free WWE Stock Research Report. Tapesty (TPR)

Luxury fashion company Tapestry Inc (NYSE: TPR) owns 3 major brands: Kate Spade; Coach and Stuart Weitzman. Now it says something when all 9 analysts covering the what is ledderhose disease stock rate TPR a ‘Buy.’ All these ratings came in the last three months. That’s with an average analyst price target of $46, indicating extremely appealing upside potential of 48%.

“We have been impressed as TPR has built out a what is ledderhose disease set of core capabilities and an operating playbook that can what is ledderhose disease be leveraged across the platform,” KeyBanc analyst Edward Yruma wrote following the company’s recent earnings report. “Despite promotional concerns, TPR continues to make progress in its Kate Spade reboot what is ledderhose disease and reiterated positive comp guidance for 4Q19.”

Yruma is particularly optimistic about new creative director Nicola Glass. Her first Kate Spade collection launched in September 2018 to what is ledderhose disease rave reviews — and stores will soon be replenished with the new products. “Increased penetration of Nicola Glass’s product is a key part of the expected positive what is ledderhose disease 4Q comp as all product in the full-price channel should be new by the end of 4Q what is ledderhose disease (while three-quarters was new in 3Q) and outlet penetration will ramp over coming quarters,” Yruma told investors. Get the TPR Stock Research Report. Sarepta Therapeutics (SRPT)

The next stock to buy jumps from the world of what is ledderhose disease fashion to the world healthcare with Sarepta Therapeutics (NASDAQ: SRPT). This $9 billion gene-therapy company already has an FDA-approved product on the market. We are talking about Exondys 51. The drug is the first-ever FDA approved treatment for a rare but deadly genetic what is ledderhose disease disease called Duchenne muscular dystrophy (DMD).

And now the FDA has granted priority review for SRPT’s second treatment. Golodirsen is for DMD patients with a different genetic mutation. That’s alongside over 20 therapies in various stages of development what is ledderhose disease and research focused on RNA, gene therapy and gene editing. In short, you can see why SRPT represents a very intriguing investing what is ledderhose disease opportunity.

Nineteen out of 20 analysts currently rate Sarepta a ‘Buy.’ The best part is that the average analyst price target what is ledderhose disease translates into 69% upside potential from current levels. “With solid sales and regulatory progress for the exon skipping what is ledderhose disease portfolio providing a continued foundation, SRPT remains fully immersed on the path towards establishing themselves what is ledderhose disease as a gene therapy leader” writes RBC Capital’s Brian Abrahams.

Rakesh made his call following Microchip’s earnings results. The company reported EPA modestly above consensus, while guiding down to a flat JunQ, citing a China trade and tariff overhang. However the key point is that MCHP continues to see what is ledderhose disease a 2H pickup with potential for stronger China stimuli. It also noted any trade resolution would be positive as what is ledderhose disease it removes uncertainty even if it implies higher tariffs.

He reiterated his bullish call following solid 1Q19 results which what is ledderhose disease also saw the company raises its 2019 guidance slightly. “We maintain our view that the shares are attractive especially what is ledderhose disease when we consider the company’s redeployment of $3.2 billion in annualized cost savings from IngenioRx to drive what is ledderhose disease long-term growth rates across its different businesses” cheers Halper. Encouragingly the company’s launch of its PBM, IngenioRx, appears to be on track for this quarter.

Anthem isn’t the only stock getting upgraded right now. Valero Energy (NYSE: VLO) is the world’s largest independent petroleum refiner and it’s also enjoying increasingly positive analyst sentiment. “We have upgraded VLO to Overweight from Neutral, as we believe that VLO is now uniquely positioned to what is ledderhose disease outperform the refining sector and the broader XLE” writes top JP Morgan analyst Phil Gresh.

Following the upgrade, VLO now scores only Buy ratings from the Street. This is a great stock to buy as it also what is ledderhose disease has an average analyst price target of $104 (24% upside potential). As Gresh explains, VLO now demonstrates the benefits of corporate structure simplicity, plus a compelling combination of solid FCF generation, a strong balance sheet and disciplined capital allocation (since Joe Gorder took over as CEO in 2015).

What’s more VLO boasts a unique position in Corpus Christi, Texas. According to the analyst the market isn’t appreciating several new crude pipelines in the region. These could direct up to 2mmbpd of light sweet crude what is ledderhose disease in 2H19-2020, well in excess of local refining capacity (~700kbd). This could lead to a material crude price discount for what is ledderhose disease Corpus area refineries, where VLO is best positioned.

Despite Chinese tensions and macro concerns, BABA still managed to report stellar earnings results. This includes a 51% year-over-year increase in revenue to ¥93.5B ($13.93 billion). As Top 50 SunTrust analyst Youssef Squali writes “We remain bullish on BABA as management once again executed what is ledderhose disease well against a challenging macro economic/political backdrop in F4Q19, beating expectations and gaining share.”

And even low guidance for FY2020 failed to disturb analysts. “Macro uncertainty and the decision to postpone monetization of the what is ledderhose disease recommendation feed have caused management to guide cautiously for FY20 what is ledderhose disease in our view, but a very healthy 33%+ Y/Y revenue guide and a compelling valuation keep us positive” the analyst concludes. Get the BABA Stock Research Report.

RELATED POSTS